<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26526589</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2015.10.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(15)30012-7</ELocationID><Abstract><AbstractText>Enteroviruses are major causative agents of various human diseases, and some of them are currently considered to be an enormous threat to public health. However, no effective therapy is currently available for the treatment of these infections. We identified gemcitabine, a nucleoside-analog drug used for cancer treatment, from a screen of bioactive chemicals as a novel inhibitor of coxsackievirus B3 (CVB3) and enterovirus 71 (EV71). Gemcitabine potently inhibited the proliferation of CVB3 and EV71, as well as the replication of CVB3 and EV71 replicons, in cells with a low micromolar IC50 (1-5&#xa0;&#x3bc;M). Its strong inhibitory effect was also observed in cells infected with human rhinoviruses, demonstrating broad-spectrum antiviral effects on enteroviruses. Mechanistically, an extensive analysis excluded the involvement of 2C, 3A, IRES-dependent translation, and also that of polyprotein processing in the antiviral effects of gemcitabine. Importantly, gemcitabine in combination with ribavirin, an antiviral drug currently being used against a few RNA viruses, exhibited a synergistic antiviral effect on the replication of CVB3 and EV71 replicons. Consequently, our results clearly demonstrate a new indication for gemcitabine as an effective broad-spectrum inhibitor of enteroviruses and strongly suggest a new therapeutic strategy using gemcitabine alone or in combination with ribavirin for the treatment of various diseases associated with enterovirus infection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyunju</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Incurable Diseases Therapeutics Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Cheongju, South Korea; College of Pharmacy, Chungbuk National University, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chonsaeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong-eun</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Incurable Diseases Therapeutics Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Cheongju, South Korea; College of Pharmacy, Chungbuk National University, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jae-Hyoung</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, Chuncheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Miri</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Incurable Diseases Therapeutics Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Cheongju, South Korea; College of Pharmacy, Chungbuk National University, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Kwangman</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Incurable Diseases Therapeutics Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Cheongju, South Korea; Department of Medical Science, Soonchunhyang University, Asan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Mingu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Incurable Diseases Therapeutics Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyungjin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hae Soo</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Jin Soo</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Janghwan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Stem Cell Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Sang-Bae</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Mi-Young</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Medical Science, Soonchunhyang University, Asan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Su Ui</ForeName><Initials>SU</Initials><AffiliationInfo><Affiliation>Natural Medicine Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chong-Kyo</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Meehyein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Hyun-Jeong</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, Chuncheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kuppeveld</LastName><ForeName>Frank J M</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Section of Virology, Department Infectious Diseases &amp; Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sungchan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Incurable Diseases Therapeutics Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Cheongju, South Korea; Department of Biomolecular Science, Korea University of Science and Technology, Daejeon, South Korea. Electronic address: sungchan@kribb.re.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0W860991D6</RegistryNumber><NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000093542">Gemcitabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093542" MajorTopicYN="N">Gemcitabine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral inhibitor</Keyword><Keyword MajorTopicYN="N">Enteroviruses</Keyword><Keyword MajorTopicYN="N">Gemcitabine</Keyword><Keyword MajorTopicYN="N">Ribavirin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26526589</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2015.10.011</ArticleId><ArticleId IdType="pii">S0166-3542(15)30012-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>